Pelvic floor dysfunction. Pelvic muscle wasting
Conditions
Interventions
Intervention 1: Intervention group: This group will receive 8 sessions of biofeedback therapy along with daily intake of 600 mg of N-acetylcysteine ??(Actover Company). Intervention 2: Control group:
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 18 to 65 years Diagnosis of pelvic floor dysfunction based on specialist examination and confirmation of the standard Pelvic Floor Distress Disorders-20 questionnaire Mild to moderate severity of pelvic floor dysfunction Ability to attend biofeedback therapy sessions and regular use of N-acetylcysteine ??supplementation Willingness to participate in the study and signing an informed consent form No drug treatment or biofeedback therapy in the past three months
Exclusion criteria
Exclusion criteria: Having neurological or muscular diseases that affect pelvic floor function (such as MS, Parkinson's, or uncontrolled diabetes) History of pelvic or abdominal surgery within the past six months Moderate to severe renal or hepatic impairment Moderate to severe renal or hepatic impairment Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of pelvic floor muscle disorder symptoms. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Pelvic floor muscle disorder questionnaire-20. | — |
Secondary
| Measure | Time frame |
|---|---|
| Health-related quality of life. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: SF-36 questionnaire.;N-Acetylcysteine ??Side Effects. Timepoint: 3 Months After Intervention. Method of measurement: History and clinical interview. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElnaz Zarinzadeh
Shahid Beheshti University of Medical Sciences
Outcome results
None listed